ArticleThe EMBO journal2003
Epigenetic consequences of AML1-ETO action at the human c-FMS locus.
Article in The EMBO journal, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 60 citations in OpenAlex.
- HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases.Chonnam medical journal · 2016Review
- TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.Molecular and cellular biology · 2015Article
- Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal.Cell reports · 2014Article
- Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2014Review
- Aberrant epigenetic regulators control expansion of human CD34+ hematopoietic stem/progenitor cells.Frontiers in genetics · 2013Review
- A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.Nature · 2013Article
- RUNX1: A microRNA hub in normal and malignant hematopoiesis.International journal of molecular sciences · 2013Review
- Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.Leukemia · 2012Article
- Article
- Mass spectrometric studies on epigenetic interaction networks in cell differentiation.The Journal of biological chemistry · 2011Article
- cis-Regulatory remodeling of the SCL locus during vertebrate evolution.Molecular and cellular biology · 2010Article
- Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin.Nature genetics · 2010Article
- Dynamic regulation of Gata1 expression during the maturation of conventional dendritic cells.Experimental hematology · 2010Article
- Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5.Oncogene · 2010Article
- AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.Cancer research · 2010Article
- Histone deacetylases and the immunological network: implications in cancer and inflammation.Oncogene · 2010Review
- Characterization of RNA aptamers that disrupt the RUNX1-CBFbeta/DNA complex.Nucleic acids research · 2009Article
- Article
- A novel mode of enhancer evolution: the Tal1 stem cell enhancer recruited a MIR element to specifically boost its activity.Genome research · 2008Article
- Chromatin regulation by AML1 complex.International journal of hematology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Although many leukaemia-associated nuclear oncogenes are well characterized, little is known about the molecular details of how they alter gene expression. Here we examined transcription factor complexes and chromatin structure of the human c-FMS gene in normal and leukaemic cells. We demonstrate by in vivo footprinting and chromatin immunoprecipitation assays that this gene is bound by the transcription factor AML1 (RUNX1). In t(8;21) leukaemic cells expressing the aberrant fusion protein AML1-ETO, we demonstrate that this protein is part of a transcription factor complex binding to extended sequences of the c-FMS intronic regulatory region rather than the promoter. The AML1-ETO complex does not disrupt binding of other transcription factors, indicating that c-FMS is not irreversibly epigenetically silenced. However, AML1-ETO binding correlates with changes in the histone modification pattern and increased association of histone deacetylases. Our experiments provide for the first time a direct insight into the chromatin structure of an AML1-ETO-bound target gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.